Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BEAT

HeartBeam (BEAT) Stock Price, News & Analysis

HeartBeam logo

About HeartBeam Stock (NASDAQ:BEAT)

Advanced Chart

Key Stats

Today's Range
$2.10
$2.30
50-Day Range
$71.46
$72.27
52-Week Range
$1.45
$3.48
Volume
118,715 shs
Average Volume
103,607 shs
Market Capitalization
$52.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Buy

Company Overview

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.

HeartBeam Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
30th Percentile Overall Score

BEAT MarketRank™: 

HeartBeam scored higher than 30% of companies evaluated by MarketBeat, and ranked 785th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    HeartBeam has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    HeartBeam has received no research coverage in the past 90 days.

  • Read more about HeartBeam's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of HeartBeam is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of HeartBeam is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    HeartBeam has a P/B Ratio of 26.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.45% of the float of HeartBeam has been sold short.
  • Short Interest Ratio / Days to Cover

    HeartBeam has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in HeartBeam has recently increased by 3.89%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    HeartBeam does not currently pay a dividend.

  • Dividend Growth

    HeartBeam does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.45% of the float of HeartBeam has been sold short.
  • Short Interest Ratio / Days to Cover

    HeartBeam has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in HeartBeam has recently increased by 3.89%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for HeartBeam this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, HeartBeam insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    18.04% of the stock of HeartBeam is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 7.77% of the stock of HeartBeam is held by institutions.

  • Read more about HeartBeam's insider trading history.
Receive BEAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HeartBeam and its competitors with MarketBeat's FREE daily newsletter.

BEAT Stock News Headlines

IBN Coverage: HeartBeam (NASDAQ: BEAT) Is One to Watch
Gold is soaring. Here’s how to get paid from it
Gold just broke through $3,300… And while the headlines shout about price targets, something even more powerful is happening behind the scenes… Some investors are using a little-known ETF to collect up to $1,152/month from gold's surge. No trading gold futures. No mining stocks. No vaults. Just a simple fund delivering monthly payouts — like clockwork.
HeartBeam Reports First Quarter 2025 Results
See More Headlines

BEAT Stock Analysis - Frequently Asked Questions

HeartBeam, Inc. (NASDAQ:BEAT) issued its earnings results on Tuesday, May, 13th. The medical research company reported ($0.18) EPS for the quarter.
Read the conference call transcript
.

HeartBeam (BEAT) raised $16 million in an initial public offering (IPO) on Thursday, November 11th 2021. The company issued 2,750,000 shares at $5.50-$6.50 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that HeartBeam investors own include NVIDIA (NVDA), Meta Platforms (META), Bristol Myers Squibb (BMY), Intel (INTC), Micron Technology (MU), PayPal (PYPL) and AbbVie (ABBV).

Company Calendar

Last Earnings
5/13/2025
Today
6/19/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
N/A
Current Symbol
NASDAQ:BEAT
Fax
N/A
Employees
1,700
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$8.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+411.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$19.45 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.06 per share
Price / Book
26.08

Miscellaneous

Free Float
27,711,000
Market Cap
$52.91 million
Optionable
Not Optionable
Beta
-0.59
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:BEAT) was last updated on 6/19/2025 by MarketBeat.com Staff
From Our Partners